Page 67 - e-CPG-SLE-8_5_24
P. 67

Management of Systemic Lupus Erythematosus

           74.  Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic
               Lupus Erythematosus. N Engl J Med. 2020;382(3):211-221.
           75.  Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in
               moderately-to-severely active systemic lupus erythematosus: the randomized,
               double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab
               trial. Arthritis Rheum. 2010;62(1):222-233.
           76.  Cobo-Ibanez  T,  Loza-Santamaria  E,  Pego-Reigosa  JM,  et  al.  Efficacy  and
               safety of rituximab in the treatment of non-renal systemic lupus erythematosus:
               a systematic review. Semin Arthritis Rheum. 2014;44(2):175-185.
           77.  Li QY, Yu F, Zhou FD, et al. Plasmapheresis Is Associated With Better Renal
               Outcomes  in  Lupus  Nephritis  Patients  With  Thrombotic  Microangiopathy:  A
               Case Series Study. Medicine (Baltimore). 2016;95(18):e3595.
           78.  Soyuoz  A,  Karadag  O,  Karaagac  T,  et  al.  Therapeutic  plasma  exchange  for
               refractory SLE: A comparison of outcomes between different sub-phenotypes.
               Eur J Rheumatol. 2018;5(1):32-36.
           79.  Monova  D,  Monov  S.  Treatment  of  active  lupus  nephritis:  intravenous
               immunoglobulin  G  versus  cyclophosphamide  or  azathioprine.  BANTAO  J.
               2006;4(2):13.
           80.  Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology
               (Oxford). 2015;54(3):383-391.
           81.  Guo Y, Tian X, Wang X, et al. Adverse Effects of Immunoglobulin Therapy. Front
               Immunol. 2018;9:1299.
           82.  Weening  JJ,  D’Agati  VD,  Schwartz  MM,  et  al.  The  classification  of
               glomerulonephritis  in  systemic  lupus  erythematosus  revisited.  Kidney  Int.
               2004;65(2):521-530.
           83.  Ministry of Health Malaysia. Management of Chronic Kidney Disease. 2nd ed.
               Putrajaya: MOH 2018.
           84.  Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients
               with  active  proliferative  lupus  nephritis:  the  Lupus  Nephritis  Assessment  with
               Rituximab study. Arthritis Rheum. 2012;64(4):1215-1226.
           85.  Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of
               Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117-1128.
           86.  Hannon  CW,  McCourt  C,  Lima  HC,  et  al.  Interventions  for  cutaneous
               disease  in  systemic  lupus  erythematosus.  Cochrane  Database  Syst  Rev.
               2021;3(3):CD007478.
           87.  Thomas  G,  Cohen  Aubart  F,  Chiche  L,  et  al.  Lupus  Myocarditis:  Initial
               Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients. J
               Rheumatol. 2017;44(1):24-32.
           88.  Mosca  M,  Tani  C,  Aringer  M,  et  al.  European  League  Against  Rheumatism
               recommendations for monitoring patients with systemic lupus erythematosus in
               clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269-
               1274.
           89.  Bertsias  G,  Ioannidis  JP,  Boletis  J,  et  al.  EULAR  recommendations  for  the
               management  of  systemic  lupus  erythematosus.  Report  of  a  Task  Force  of
               the  EULAR  Standing  Committee  for  International  Clinical  Studies  Including
               Therapeutics. Ann Rheum Dis. 2008;67(2):195-205.
           90.  Chen  D,  Xie  J,  Chen  H,  et  al.  Infection  in  Southern  Chinese  Patients  with
               Systemic Lupus Erythematosus: Spectrum, Drug Resistance, Outcomes, and
               Risk Factors. J Rheumatol. 2016;43(9):1650-1656.
           91.  Wu  Q,  Liu  Y,  Wang  W,  et  al.  Incidence  and  prevalence  of  tuberculosis  in
               systemic lupus erythematosus patients: A systematic review and meta-analysis.
               Front Immunol. 2022;13:938406.


                                      50
   62   63   64   65   66   67   68   69   70   71   72